Boundless Bio, Inc. (BOLD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Boundless Bio, Inc. on March 9, 2026, covering events occurring on March 3, 2026. The filing primarily serves to announce the departure of a director and references a separate press release regarding financial results for the fourth quarter and full year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
- Board Resignation: Effective March 3, 2026, Christine Brennan, Ph.D., resigned from the Board of Directors.
- Reason for Departure: Dr. Brennan is assuming a new role at Johnson & Johnson Development Corporation.
- Disagreement Status: The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, or management commentary on future performance. It notes that the financial results for the period ended December 31, 2025, were announced via a press release on March 9, 2026. No specific risks or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 9, 2026) for actual Q4 and full-year 2025 financial figures.
- Confirm the composition of the Board of Directors following Dr. Brennan's resignation.
- Verify if the Company has appointed a replacement director to fill the vacancy.
- Check for any subsequent filings regarding the Company's cash position or burn rate, as these are not disclosed in this 8-K.